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Abstract
Serodiagnosis of arthropod-borne viruses (arboviruses) at the Division of Vector-Borne Diseases, CDC, employs a
combination of individual enzyme-linked immunosorbent assays and microsphere immunoassays (MIAs) to test for
IgM and IgG, followed by confirmatory plaque-reduction neutralization tests. Based upon the geographic origin of a
sample, it may be tested concurrently for multiple arboviruses, which can be a cumbersome task. The advent of
multiplexing represents an opportunity to streamline these types of assays; however, because serologic cross-
reactivity of the arboviral antigens often confounds results, it is of interest to employ data analysis methods that
address this issue. Here, we constructed 13-virus multiplexed IgM and IgG MIAs that included internal and external
controls, based upon the Luminex platform. Results from samples tested using these methods were analyzed using 8
different statistical schemes to identify the best way to classify the data. Geographic batteries were also devised to
serve as a more practical diagnostic format, and further samples were tested using the abbreviated multiplexes.
Comparative error rates for the classification schemes identified a specific boosting method based on logistic
regression “Logitboost” as the classification method of choice. When the data from all samples tested were combined
into one set, error rates from the multiplex IgM and IgG MIAs were <5% for all geographic batteries. This work
represents both the most comprehensive, validated multiplexing method for arboviruses to date, and also the most
systematic attempt to determine the most useful classification method for use with these types of serologic tests.
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Introduction
Arthropod-borne viruses (arboviruses) are responsible for
considerable morbidity and mortality worldwide. Those most
heavily affected live at tropical latitudes where mosquitoes are
most active and difficult to control [1]. Human vaccines are
available for yellow fever (YF), Japanese encephalitis (JE) and
tick-borne encephalitis (TBE) viruses, and long-sought vaccine
candidates for dengue are in various stages of clinical trials [2].
However, for most of the world’s population, vaccines for these
viruses are currently either unavailable or too expensive.
Clinical presentations can be ambiguous and diagnoses
notoriously difficult based on symptoms alone. Laboratory
confirmation is therefore often critical for diagnosis. While
arboviral infections could potentially be treated using antivirals
such as Ribavirin [3], and is occasionally treated with IVIG,
currently the usual treatment is supportive therapy only. The
presence of viral RNA in blood is typically fleeting, so antibody
testing is often the method of choice to provide a laboratory
diagnosis or to help rule in or rule out other more treatable
infections.
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A variety of techniques have been developed over the past
40 years for the serodiagnosis of arboviruses. These include
immunofluorescence assay, complement fixation test,
hemagglutination inhibition assay, plaque reduction
neutralization test (PRNT) [4], and IgM and IgG enzyme-linked
immunosorbent assays (ELISAs) [5,6]. The most recent
addition to the menu of tests is the microsphere immunoassay
(MIA) [7,8]. Currently, ELISAs and MIAs are generally used as
screening tools to separate those specimens that are negative
to the arboviral antibody tested for, from those that should
receive confirmatory testing. In a known outbreak situation, IgM
and IgG assays are sometimes performed without using
confirmatory methods. A combined approach enables the
broadest spectrum of information to be captured and
interpreted in light of the clinical picture, any travel history of
the patient, and timing of specimen collection.
A critical part of arboviral laboratory diagnosis pertains to the
serologic testing for related viruses. Antibodies to one virus of a
particular genus will frequently cross-react with heterologous
antigens within the genus [7]. Much effort has been put into the
development of tests and reagents that reduce or remove this
cross-reactivity [9]. If successful, such methods would reduce
the need for confirmatory testing with PRNT. However, the
cross-reactivity seen using currently available reagents can be
taken advantage of. The possession of an understanding of the
cross-reactivities of these viruses both inform diagnoses, and
help in the recognition of viruses formerly absent from a
particular geographic region [10]. At the CDC Arboviral
Diseases Branch, laboratory diagnosis typically employs the
geographic approach to testing. The initial screening
incorporates a number of arboviruses known to be present in
the region of the world where the patient resides or has
recently traveled to.
Microsphere-based immunoassays (MIAs) have been used
as screening tools for arboviruses over the past 5 years. A
number of US State and government labs including the CDC
have used a duplex IgM tests for detection of antibodies to
West Nile (WN) and St. Louis encephalitis (SLE) viruses [7],
and have participated in proficiency testing using this method.
This test was recently adapted for the detection of IgG to WN
and SLE viruses (unpublished data). The speed and ease of
use of these methods have made them attractive for expansion
to other arboviruses, where viral antigens of interest can be
incorporated into the testing battery. The body of work
presented here elaborates on these methods and capitalizes
on the multiplexing capability of the Luminex platform. The
creation of IgM and IgG multiplex MIAs allows for a
comprehensive array of arboviral infections to be tested for
concurrently. The large and complex data set that results from
extensive multiplexing necessitates a thorough investigation of
classification methods in order to identify the most effective
technique. It must allow both flexibility of use and the ability to
accommodate the inherent cross-reactivity of these viruses.
Here we report the development of multiplex microsphere
immunoassays for detection of IgM and IgG to 6 flaviviruses, 6
alphaviruses, and 1 bunyavirus of human importance,




The Division of Vector-Borne Diseases Human Subjects
Advisor to the Centers for Disease Control and Prevention
Institutional Review Board reviewed the procedures for
“Multiplex Microsphere Immunoassays for the Detection of IgM
and IgG to Arboviral Diseases” and confirmed that they do not
meet the definition of research involving human subjects
specified by 45 CFR 46.102(f). CDC IRB review was not
required because specimens involved in this study were
originally collected as part of standard CDC diagnostic
operations and are archived expressly for development and
testing. These specimens had all donor identification material
removed at the time they entered the archive. Because data
will be non-identifiable, this activity does not involve human
subjects.
The suckling mouse brain antigens used in this study were
made at the Centers for Disease Control and Prevention under
the guidance of the Centers for Disease Control and
Prevention-Fort Collins Institutional Animal Care and Use
Committee (IACUC), protocol 11-013. Pain and suffering was
minimized by hypothermia to effect during inoculation followed
by return of the animals to their mother; euthanasia was
performed at the first signs of illness including reduced milk
intake. Animals were euthanized using isofluorane by
inhalation to effect and hypothermia to effect as specified by
the IACUC. Antigens produced under this protocol were not
made specifically for this study but were made in accordance
with the specific mission of the Centers for Disease Control and
Prevention to provide reference quantities of reagents for
arboviruses, and are made widely available.
Specimens
Identifying information was removed from serum and
cerebrospinal fluid (CSF) specimens obtained from the DVBD
diagnostic archives (Tables 1 and 2). The samples had
previously been screened for anti-arboviral antibodies using
one of the currently employed diagnostic IgM protocols
(specifically IgM-capture ELISA (MAC-ELISA) [5], WN/SLE IgM
MIA [7], or EEE IgM MIA (unpublished method)) or one of the
IgG protocols (IgG-ELISA [6] or WN/SLE IgG MIA (unpublished
method)) for serum only. A confirmatory plaque reduction
neutralization test (PRNT) [4] was previously performed for all
serum samples that produced positive IgM screening results,
and for all samples that were submitted specifically for vaccine
titer confirmation. Panels of serum samples were assembled to
determine the initial classification parameters for the multiplex
IgM microsphere immunoassay (multiplex IgM-MIA) and
multiplex IgG-MIA. Infecting viruses were: flaviviruses dengue
(DEN), Japanese encephalitis (JE), Powassan (POW), SLE,
WN, and yellow fever (YF); alphaviruses eastern equine
encephalitis (EEE), Mayaro (MAY), Chikungunya (CHIK), Ross
River (RR), Venezuelan equine encephalitis (VEE), and
California serogroup bunyavirus La Crosse encephalitis (LAC).
While alphavirus western equine encephalitis virus (WEE)
antigen was included in the tests, samples were unavailable. A
panel of samples previously resulting in negative arboviral
Multiplex IgM and IgG Immunoassays for Arboviruses
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diagnoses was assembled (NEG). Numbers of sera per virus
are listed in Table 1 in the “Initial” serum columns. Additional
samples were assembled to investigate the use of geographic
batteries (Table 1 “Geo Val” columns) and finally, samples
submitted to the DVBD Arbovirus Diseases Activity diagnostic
lab in the summer of 2011 were analyzed to validate the
methods (Table 1 “2011” serum columns). No samples were
available for WEE virus, and the VEE and YF samples were
from vaccinees. Additional panels of sera were compiled for
syndromes clinically similar to some arboviruses as follows:
syphilis (N=58), Lyme disease IgM (N=10), Lyme disease IgG
(N=10), rheumatoid factor (N=13) and anti-nuclear antibody
(N=22). To determine if the multiplex IgM method was useful
for the testing of CSF a panel of 131 samples comprising IgM-
positives to WN (N=24), LAC (N=11), and JE (N=3) and POW
(N=3) viruses and YF vaccine (N=1), plus antibody-negative
samples (N=89) was assembled.
Table 1. Samples tested in the IgM and IgG multiplex MIAs
listed by virus.
 IgM IgG  
 Serum CSF  Serum     
Truth* Initial Geo Val 2011 Initial 2011 Total Initial Geo Val 2011 Total  
NEGIgM 79 64 222 19 70 454 93 54 173 320  
CHIKIgM 44 7 10 0 0 61 45 1 1 47  
DENIgM 64 22 3 0 0 89 72 0 1 73  
EEEIgM 34 0 2 0 0 36 39 0 0 39  
JEIgM 29 0 1 2 1 33 28 0 1 29  
LACIgM 33 4 41 5 6 89 35 0 9 44  
MAYIgM 4 1 2 0 0 7 4 0 1 5  
POWIgM 7 2 13 0 3 25 6 2 8 16  
SLEIgM 54 2 0 0 0 56 61 0 0 61  
VEEIgM 6 0 0 0 0 6 16 0 0 16  
WNIgM 66 3 24 12 12 117 78 3 23 104  
YFIgM 81 11 9 1 0 102 39 9 11 59  
Non-arbo 103 0 0 0 0 103 103 0 0 103  
Total 604 116 327 39 92 1178 619 69 228 916  
*. Based upon previous IgM/IgG ELISA/MIA and PRNT results
doi: 10.1371/journal.pone.0075670.t001
Table 2. Samples tested by IgM and IgG multiplex MIAs
listed by geographic battery.
 IgM IgG
 Serum CSF  Serum    
Battery Initial* Geo Val 2011 Initial* 2011 Total Initial* Geo Val 2011 Total
US 273 42 233 36 80 664 312 31 175 518
CSAM 393 39 25 32 4 493 402 25 18 445
AAE 375 35 69 34 8 521 361 13 35 409
*. Samples were tested in all batteries in which the infecting virus appeared
doi: 10.1371/journal.pone.0075670.t002
Assay controls
Controls were developed to confirm that components had
been added correctly to the tests and to confirm sample
characteristics and system integrity. Flavivirus group-reactive
MAb DEN 4G2 [11], alphavirus group-reactive MAb EEE
1A4B-6 [12], and California serogroup bunyavirus group-
reactive MAb LAC 10G5.4 [13] were each conjugated to
phycoerythrin by Prozyme Inc., San Leandro, CA. These were
used to test for antigen reactivity by adding to a well containing
the other test components. A negative serum sample,
previously tested for antibodies to all arboviruses, was added
to a well on the plate containing all the other test components
to serve as a baseline for the assay. The following internal
control sets of microspheres, made by Radix BioSolutions,
Georgetown, TX, were added to all wells of the assay: control
to monitor nonspecific binding of detection reagents, instrument
reporter laser control, serum addition control (IgM + IgG), IgM
reporter addition control (IgM test only), IgG reporter addition
control (IgG test only) and rheumatoid factor control (RF, IgM
test only). The internal controls were used with the summer
2011 evaluation samples only.
Coupling of microspheres to monoclonal antibodies
Because purified antigens were not available for many of the
viruses involved in the multiplex MIA, capture of the antigens
was achieved using monoclonal antibodies (MAbs) coupled to
the microspheres. Three MAbs were used: flavivirus group-
reactive 6B6C-1 [14], alphavirus group-reactive 2A2C-3 [15],
and anti-LAC 807-22 [13]. For each viral antigen, 25 µg of the
appropriate purified antibody was covalently coupled to 5.4
million carboxylated MicroPlex® microspheres (Luminex
Corporation, Austin, TX), using standard carbodiimide
methodology. Hence, 6 microspheres sets of different spectral
addresses were coupled to 6B6C-1 to accommodate the
flaviviral antigens, 6 sets were coupled to 2A2C-3 (for the
alphaviral antigens), and a single set was coupled to 807-22
(for the bunyaviral antigen). All coupled microsphere sets were
adjusted to a concentration of 5x106 microspheres/ml and
stored at 4°C for up to 18 months thereafter, as determined
empirically.
Addition of antigens to coupled microspheres
Viral antigens were prepared in either suckling mouse brain
(SLE, POW, YF, VEE, MAY, RR, CHIK, EEE, WEE, LAC) or
were engineered recombinants expressed in COS-1 cells (WN
[16], DEN 2 [17] combined with DEN 3 (unpublished), and JE
[18]. Antigens were produced at the CDC/DVBD with the
exception of the WN viral recombinant antigen, which was
provided as a gift by Hennessy Research, Shawnee, KS. The
optimal amount of viral antigen to add to the coupled
microsphere sets varied depending on the individual antigen
and varied between lots. This was initially determined by
titration using known antibody-positive serum controls to each
virus and compared to a negative serum control, and the
working dilution was chosen to yield a median fluorescent
intensity (MFI) of approximately 2000 for the positive controls.
For the IgM assays, positive and negative sera were IgG-
depleted using protein G sepharose prior to use. Antigen
Multiplex IgM and IgG Immunoassays for Arboviruses
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volumes per ml of antigen/coupled microsphere stock
preparation ranged from 0.75 µl to 160 µl. In addition, negative
(mock) antigens (suckling mouse brain (NSMB) and
recombinant (NREC)) were added to separate sets of
microspheres. The volumes used for the negatives were
equivalent to those of the antigens for each virus family that
required the most volume and were included in the test to
identify nonspecific background reactions of the serum with
both the coupling monoclonal antibody and any non-viral
protein in the antigen preparations [19]. Coupled microspheres
and antigens were mixed together in Candor Antibody
Stabilizer (Boca Scientific, Boca Raton, FL) on a rotating
platform for 1 h at room temperature, after which they were
stored in the dark at 4°C for a minimum of 12 hours prior to use
and up to 6 months thereafter, as determined by previous
stability experiments (unpublished). Microspheres were at a
concentration of 5 x 105/ml in these stock solutions, which were
generally made in 2 ml batches. The same preparation of
antibody-coupled microspheres/antigen was used for both IgM
and IgG MIAs for each virus. The microsphere regions (sets)
used in these experiments were as follows: 6B6C-1 {11 (WN),
12 (SLE), 13 (POW), 14 (DEN2/3), 15 (JE), 16 (YF), 18
(NSMB), 19 (NREC)}; 2A2C-3 {21 (VEE), 22 (MAY), 24 (RR),
25 (CHIK), 26 (EEE), 27 (WEE), 28 (NSMB)}; 807-22 {51
(LAC), 52 (NSMB)}.
Preparation of samples
For the IgM-MIA, it was desirable to remove potentially
interfering IgG from the serum. The samples were diluted 1:20
in PBS then reacted with protein G sepharose in a 96-well filter
plate Millipore Corporation, Billerica, MA) for 30 min at room
temperature as previously described [7]. The plate was filtered
using a vacuum manifold (Pall Corporation, Ann Arbor, MI) and
the filtrates captured in a round-bottomed 96-well plate.
Samples were further diluted to 1:400 [7] using 50% Low Cross
Buffer in PBS pH 7.2 (Boca Scientific, Boca Raton, FL) prior to
use. For the IgG-MIA, no prior treatment was necessary and
samples were diluted to 1:400 in 50% LCB in PBS prior to use.
To minimize pipetting errors and to make transfer to the MIA
plates as convenient as possible, samples were placed
identically on the serum dilution plates for IgM and IgG, in the
order and position that they would appear on the MIA plates.
Cerebrospinal fluid samples required no protein G treatment
and were diluted 1:5 in 50% LCB in PBS.
IgM and IgG-MIA
To maximize efficiency and conserve supplies, IgM and IgG-
MIAs were prepared concurrently. Two filter plates were
prewetted with 150 µl PBS, one for the IgM and one for the IgG
assay. A cocktail of viral antigens/antibody-coupled
microspheres was made that included all 13 regions of
microspheres associated with the viral antigens. A volume of 5
µl per microsphere region for each assay well was added to a
single polypropylene tube, and undiluted LCB was used to
make up the total volume so that 150 ul/well of the cocktail
could be added to both plates. Similarly a cocktail containing
the negative antigens/antibody-coupled microspheres was
made that included all 4 negative antigen sets, using 5 µl of
each set for each well, and undiluted LCB was used to make
up the volume so that for 50 µl/well could be added to both
plates. The negative cocktail was vortexed thoroughly and
divided into 2 equal parts: one for the IgM assay and one for
the IgG assay. For the IgM test 0.25 µl/well each of the internal
controls: nonspecific control (region 53), serum verification M
+G control (region 30), instrument reporter laser control (region
97), rheumatoid factor (RF) control (region 42), and reporter
control M (region 47) was added to the negative antigen
cocktail. For the IgG test, 0.25 µl/well each of the internal
controls: nonspecific control (region 53), sample control M+G
(region 30), reporter laser control (region 97), and reporter
control G (region 33) was added to the negative antigen
cocktail. Antigen detection controls were prepared in 50% LCB
in PBS (4G2-PE at 8 µg/ml; 1A4B-6-PE and 10G5.4-PE at 4
µg/ml). A negative control serum was diluted to 1:400 in 50%
LCB in PBS. The PBS was suctioned from the plates using a
vacuum manifold. During all vacuum and wash steps, care was
taken so that the filters did not completely dry out, which can
cause aggregation of the microspheres and inconsistent
results. The viral antigen/antibody-coupled microsphere
cocktail was vortexed, and 150 µl was added to all control and
test wells on both plates. This was immediately suctioned
through the plate and the wells washed twice with 150 µl of
PBS. Fifty microliters per well of vortexed IgM negative antigen
cocktail plus internal controls were added to the IgM-MIA plate,
and similarly the IgG negative antigen cocktail plus internal
controls were added to the IgG plate. The addition of the
negative antigens as a separate step was performed in order to
avoid any contamination of the negatives with unbound viral
antigens that would occur if the cocktails of viral and negative
antigens on their respective antibody/beadsets were prepared
in one tube. The wells were washed twice with PBS using the
vacuum manifold, and the undersides of the plates were blotted
to prevent capillary leakage in the next steps. To the IgM plate,
50 µl per well of 4 µg/ml donkey anti-human IgM R-
phycoerythrin (Jackson Immunoresearch, West Grove, PA) in
50% LCB in PBS was added. Fifty microliters of the antigen
detection controls 4G2-PE, 1A4B-6-PE and 10G5.4-PE were
added to the first 3 wells on the plate in that order, and 50 µl of
the negative serum control was added to the 4th well. The IgG-
depleted test serum samples at 1:400 and the CSF samples at
1:5 were transferred from the preparation plate to the
subsequent wells on the plate at a rate of 50 µl/well. To the IgG
plate, the antigen detection and negative controls were added
to the first 4 wells, and the test serum samples at 1:400 were
transferred to the subsequent wells. The undersides of both
plates were blotted and the wells were covered with plate
sealer. The plates were vortexed for 10 seconds on a flat
surface vortexer to mix the well contents, the undersides
blotted, the plates covered with aluminum foil-lined lids, and
placed on a rotary plate shaker. The IgM plate was shaken for
1.5 hours at room temperature. The IgG plate was shaken for
45 minutes at room temperature, washed twice with PBS, and
50 µl/well of donkey anti-human IgG R-phycoerythrin (Jackson
Immunoresearch, West Grove, PA) in 50% LCB in PBS was
added. The underside of the plate was blotted followed by
vortexing to mix the contents of the wells. The plate was
Multiplex IgM and IgG Immunoassays for Arboviruses
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shaken a further 15 minutes then washed twice with PBS. The
underside was again blotted and 100 µl/well of BioPlex sheath
fluid (BioRad, Hercules, CA) was added. The contents of the
wells were resuspended and the median fluorescent intensity
(MFI) values were obtained for the individually identifiable
microsphere sets corresponding to the different antigens in
each well using a calibrated and validated BioPlex 100
machine (BioRad, Hercules, CA). During results acquisition for
the IgG plate, the incubation step for the IgM-MIA was
completed and wells were washed twice with PBS, the
underside of the plate blotted, and 100 µl/well BioPlex sheath
fluid was added. The plate was placed in the dark until the IgG-
MIA results acquisition was finished, after which the contents of
the IgM plate were resuspended, the plate blotted, and results
acquired. This method was used to test the initial serum
samples and CSF samples detailed in the specimens section
(Table 1).
Analysis methods
We implemented and evaluated 8 classification methods to
select the approach that would provide the best performance
over the range of data generated for the initial serum sample
set. The methods considered were 1) simple classification by
determining which antigen yielded the highest V/N (MFI of
sample reacted on viral antigen /MFI of sample reacted on
negative antigen) (MAX.V); 2) highest P/N (MFI of sample
reacted on viral antigen /MFI of negative control reacted on
viral antigen) (MAX.P); 3) individual antigen receiver operating
characteristic (ROC) curve analysis; 4) linear discriminant
analysis (LDA); 5) multinomial logistic regression (MLR); 6)
support vector machines with linear basis (SVM-LIN); 7)
support vector machines with radial basis (SVM-RAD); and 8)
LogitBoost, a specific boosting method (LOGITBOOST) [20].
All methods were implemented in the R statistical software
package (R Development Core Team (2012)) [21]. In order to
apply the different classification schemes, each sample in the
dataset was labeled according to its known infecting virus
based on previous diagnostic results using IgM-ELISA, IgG-
ELISA, and PRNT. The known negatives were so labeled.
These labels constituted “truth” with respect to classification
status. Models were developed for each classification method
using truth versus the multiple, multivariate MFI measurements
for the samples. Each classification method was fit to the full
dataset and was then used to predict the infecting virus for
each sample. A prediction error occurred when the model
predicted a result other than “truth”. To provide a further
measure of predictive performance, cross-validation was used,
where the full dataset was divided in half randomly, ensuring
that each virus set was equally split. One half of the data, the
test set, was removed, and all the classification methods were
fit on the remaining data – the training set. The resulting fits
were then used to predict the infecting virus or negativity of the
samples in the test set, and the resulting prediction was
recorded and compared with the truth. This random split was
repeated 10 times, each of which provided an estimate of the
expected error rate for all the classification methods. Finally,
these were averaged and recorded as cross-validation error
estimates (and associated confidence intervals) for each of the
methods. The method with the lowest cross-validation errors
for both true positives (sensitivity) and true negatives
(specificity) as well as for the overall error rate was chosen as
the classification method for the multiplex MIA. If two methods
were effectively tied in this performance, the method that was
easier to interpret and to implement in an Excel Add-in (macro)
for data manipulation was chosen.
Validation based on geographic batteries
The IgM and the IgG-MIAs as described above contain 13
viral antigens. As a preliminary investigation into the use of
geographic batteries, the panel of antigens in each multiplex
was divided into 3 smaller panels: WN, SLE, POW, EEE, WEE
and LAC for United States of America and Canada (US); WN,
POW, DEN, JE, YF and CHIK for Asia/Africa/Europe (AAE);
WN, SLE, DEN, YF, VEE, MAY, EEE and WEE for Central/
South America (CSAM). The RR antigen was not included in
any of the batteries. The data from the classifying sample set
were allocated to all batteries containing the infecting virus. All
8 classification methods were applied, where the data used
included only the information pertinent to the antigens in the
assigned geographic battery. Separate classification rules were
obtained for each analysis method for each geographic battery.
An additional smaller sample set obtained from the DVBD
diagnostic archives containing samples that were not included
in the original serum set was assembled as a means to
evaluate a modified laboratory methodology and to determine
classification parameters specific to the geographic batteries
(see Table 1 “Geo Val” columns for specimen details). The
methods described above were modified to include only the
specific geographic battery antigens in the antigen/bead
cocktails. Hence, 3 viral antigen cocktails were prepared.
Because the AAE and CSAM batteries did not include LAC, the
bunyavirus control 10G5.4-PE was not included for these tests.
The only other modifications for this set were that the reduced
number of antigens allowed for the volumes of viral antigen
cocktails per well to be reduced to 100 µl, and the wash
volumes to be reduced similarly. For diagnostic purposes the
usual setup would be to incorporate all 3 batteries on one IgM-
MIA and one IgG-MIA plate in series, with the antigen detection
and negative controls preceding each sample set for each
battery. Results were analyzed based on the classification
parameters created by splitting the initial sample set into
geographic batteries.
Summer 2011 samples used to validate the multiplex
MIAs
Diagnostic serum and CSF submissions during the period
May 2011 to September 2011 were tested for evidence of
arboviral antibodies using current methodology to confirm
positive reactions. After testing and reporting was complete,
remaining samples were archived, de-identified, and used to
validate the multiplex MIAs. A total of 419 samples were tested
in the IgM multiplex MIAs; 228 samples were tested in the IgG
multiplex MIAs (see Tables 1 and 2 for details). Results were
analyzed using the most successful of the classification
schemes (Logitboost and MLR) described above.
Multiplex IgM and IgG Immunoassays for Arboviruses
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Results
The multiplex MIAs were initially performed to analyze serum
and CSF antibodies reactive with 13 arboviral antigens, and to
determine which classification method might be most
successful for these data. The raw untransformed data showed
that for many samples there was a discernible MFI difference
between reactions with the homologous virus and the other
arboviral antigens. Examples of these reactions for the IgM
multiplex can be seen in Table 3. In the IgM test, approximately
91% of samples in the negative group had MFIs of less than
100 to viral antigens, whereas samples in the viral-positive
groups had MFIs on a continuum from 100 to 10,000 to
homologous viral antigens. The inherent background of the IgG
test was higher than for the IgM test, with only 62% of negative
samples exhibiting MFIs less than 100 to viral antigens, with
the remainder varying up to 2,000. Samples in the viral-positive
groups had MFIs of roughly 500 to 24,000. The overlap in MFI
values between high negative and low positive samples, and
between reactions to antigens of heterologous viruses are the
scenarios in which choosing an appropriate classification
scheme becomes particularly important. The overall variation
and separation of the V/N and P/N measurements of samples
tested on individual antigens in both IgM and IgG tests is
illustrated in Figure S1a-d.
Choice of classification method
To obtain an initial indication of which classification method
would fit the multiplex MIA data the best, we surveyed 8
approaches that ranged from simple (such as highest V/N
wins) to more rigorous methods that require complex
computation. The methods evaluated were: 1) MAX.P; 2)
MAX.V; 3) ROC; 4) LDA; 5) MLR; 6) SVM-LIN; 7) SVM-RAD;
and 8) LOGITBOOST. Methods 3-8 used both V/N and P/N
values, as it appeared that some viruses performed better with
V/N than P/N and vice-versa, as illustrated in Figure S1a-d.
Each measurement (V/N and P/N) was included so that their
contributions to classification could be evaluated. Prediction
error rates for the IgM multiplex MIA generated using these
methods (except for ROC to which overall error rates do not
pertain) showed that for the full dataset, the ranking of overall
error rates were: LOGITBOOST < SVM-RAD < MLR < SVM-
LIN < MAX.P < MAX.V < LDA. When cross-validation was
applied to the data, overall error rates rankings were:
LOGITBOOST < SVM-LIN < MAX.P < MAX.V < SVM-RAD <
MLR < LDA. For the IgG multiplex MIA, the order of error rates
were LOGITBOOST < MLR < SVM-RAD < SVM-LIN < LDA <
MAX.P < MAX.V. Error rates from cross-validation of the IgG
test were ranked: LOGITBOOST < SVM-LIN < LDA < SVM-
RAD < MAX.P < MLR < MAX.V. Logitboost therefore yielded
the lowest error rates for both assays for both the full data set
and the cross-validation of the data sets. Using Logitboost,
overall error rates of 0.4% and 0% resulted from the full data
set for IgM and IgG assays respectively, and error rates of
11.5% and 8.3% resulted from the cross-validation for the IgM
and IgG assays respectively. The higher error rates seen for
cross-validation (“test”) are expected and provide a measure of
anticipated prediction error for future use. Individual error rates
for the viral antigens and overall rates for all the methods
except ROC are shown in Tables 4 and 5. Based on this initial
survey of methods where 13 viral antigens are included in the
IgM and the IgG analyses, LOGITBOOST was the most
successful of the classification methods that considers all virus
groups simultaneously. It should be noted that to report
sensitivities and specificities for these methods would be
misleading because these metrics do not pertain to analyses of
multiple viruses; hence error rates are a more informative and
intuitive representation of truth.
Table 3. Median fluorescent intensities (MFIs) on each antigen for selected samples tested in the IgM multiplex MIA.
 Coupling Mab               
 6B6C-1 6B6C-1 6B6C-1 6B6C-1 6B6C-1 6B6C-1 6B6C-1 6B6C-1 2A2C-3 2A2C-3 2A2C-3 2A2C-3 2A2C-3 2A2C-3 807-22 807-22
Dx result* WN SLE POW DEN 2/3 JE YF NSMB N rec** CHIK EEE WEE VEE MAY NSMB LAC NSMB
CHIK IgM+ 36 23 28 34 43 24 121 97 904 37 243 65 272 38 99 311
DEN 1 1° IgM+ 672 256 184 7378 312 251 39 27 26 43 15 66 86 77 19 43
DEN 3 2° IgM+ 41 47 20 2191 57 73 43 34 79 67 27 157 75 75 26 52
EEE IgM+ 12 12 13 186 28 15 29 22 16 2915 164 99 220 20 36 62
JE IgM+ 260 161 67 598 3850 75 159 135 74 74 27 246 493 97 184 341
LAC IgM+ 6 6 10 46 5 13 21 15 14 20 9 50 77 43 1363 31
MAY IgM+/YF+ 17 13 36 225 13 543 71 52 107 35 30 71 763 50 55 66
POW IgM+ 7 15 5110 168 35 16 97 72 35 17 8 66 86 17 14 30
SLE IgM+ 396 1950 47 1094 156 189 35 37 37 45 33 101 86 58 91 106
VEE IgM+ 10 10 13 33 25 150 245 185 87 214 42 5072 136 216 98 98
WN IgM+ 4908 284 35 455 221 101 62 35 44 50 26 195 183 76 97 126
YF IgM+ 20 87 18 191 71 3990 16 13 10 16 9 26 58 25 21 32
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Because ROC compares individual virus groups to the
negative group only, it differs from the other classification
methods, and error rates for this method are reported in Table
6. The ROC analysis included individual error rates calculated
based on calculated cutoff values for V/N and P/N results, and
also results using V/N and P/N values of 2 as a cutoff, in order
to compare the calculated cutoffs to the traditional ELISA cutoff
of 2 for all viruses. In the event that geographic batteries were
not appropriate to use, ROC would be the method of choice.
The decision to use V/N or P/N with a calculated ROC cutoff or
a cutoff of 2 for the IgM test is virus-dependent, although V/N
with a calculated ROC cutoff was generally more successful
than the other variants. By contrast, clearly the best ROC
method across all viruses in the IgG multiplex was to use V/N
with a calculated cutoff. As might be anticipated, the instances
where a cutoff of 2 improved the error rates compared to the
data-derived cutoff, the calculated cutoff was close to 2. This
indicated that as a general rule, cutoffs calculated for the
individual viruses were more useful.
Table 4. IgM multiplex MIA error rates (%) for each virus based on initial serum set.
   LDA  SVM Linear SVM Radial Multi Lin Reg Max. Value V/N Max Value P/N LogitBoost
IgM Virus N Full* Test** Full Test Full Test Full Test Full Test Full Test Full Test
 CHIK 46 30.4 29.4 6.5 8.7 0 47.8 0 34.8 15.2 12 4.4 4 0 15
 DEN 66 57.6 47.5 13.6 20.7 1.5 27.6 3 40.6 9.1 10.3 9.1 15.4 1.5 9.4
 EEE 38 52.6 50 10.5 19.1 2.6 57.1 0 42.9 15.8 5.6 21.1 11.1 0 5
 JE 29 17.2 0 6.9 10.5 0 21.1 0 64.3 6.9 9.1 3.5 0 0 30.8
 LAC 34 32.4 29.4 17.7 20 0 30 0 33.3 17.7 18.8 8.8 12.5 0 0
 MAY 4 25 100 0 0 0 0 0 100 50 100 75 100 0 66.7
 NEG 82 3.7 6.7 4.9 11.4 1.2 22.9 3.7 30.8 74.4 65.8 70.7 73.7 1.2 17.7
 POW 7 14.3 0 0 0 0 100 0 66.7 0 0 0 0 0 0
 SLE 57 28.1 42.9 8.8 7.7 0 11.5 0 16 10.5 13.8 3.5 3.5 0 4.4
 VEE 6 50 20 33.3 25 0 100 0 100 33.3 40 50 60 0 0
 WN 68 41.2 35.1 13.2 12.5 1.5 10 4.4 30.3 1.4 0 2.9 2.5 0 5.4
 YF 87 69 64.4 24.1 44.7 1.2 15.8 2.3 18.8 26.4 35.1 14.9 18.9 0 10.9
 Overall 524 38.4 36.4 12.4 19.2 0.9 28.6 1.9 35.1 23.3 21.4 19.9 20.3 0.4 11.5
*. Full sample set was used to derive the classification parameters and error rates of entire sample set were determined based on these parameters.
**. Test (cross-validation) pertains to the full sample set that was divided by 2 and one half was used to determine the classification parameters and the other half was tested
using these parameters
doi: 10.1371/journal.pone.0075670.t004
Table 5. IgG multiplex MIA error rates (%) for each virus based on initial serum set.
   LDA  SVM Linear SVM Radial Multi Lin Reg Max. Value V/N Max Value P/N LogitBoost
IgG Virus N Full* Test** Full Test Full Test Full Test Full Test Full Test Full Test
 CHIK 45 17.8 9.1 4.8 7.8 3.8 11.8 0 19.2 77.8 63.2 20 21.1 0 0
 DEN 75 14.7 5.7 0 0 0 33.3 1.3 20 4 4.2 44 33.3 0 6.1
 EEE 40 15 10 5.3 22.5 4 20 0 40 35 33.3 15 9.5 0 12.5
 JE 28 35.7 30.8 2.5 5 2.5 15 0 23.1 14.3 5.9 7.1 0 0 9.1
 LAC 35 25.7 30.4 3.6 35.7 0 35.7 2.9 16.7 11.4 20 8.6 0 0 5.6
 MAY 4 0 0 5.7 10.5 2.9 31.6 0 100 0 0 100 100 0 0
 NEG 105 5.7 7.7 0 33.3 0 100 2.9 21.6 73.3 73.5 59.2 59.2 0 3.7
 POW 6 33.3 25 0 33.3 0 66.7 0 100 0 0 0 0 0 50
 SLE 62 29 18.2 3.2 13.8 1.6 24.1 0 24.1 19.4 17.2 0 0 0 18.8
 VEE 16 31.3 22.2 0 0 0 83.3 0 40 100 100 42.9 42.9 0 0
 WN 79 22.8 27.8 2.5 12.2 2.5 7.3 0 39 17.7 14 6 6 0 7.7
 YF 39 41 42.1 10.3 12.5 2.6 18.8 2.6 25 7.7 7.1 7.1 7.1 0 13.3
 Overall 534 20.4 18.2 3.9 12.6 2.4 22.6 1.1 28.4 33.9 29.6 22.6 22.6 0 8.3
*. Full sample set was used to derive the classification parameters and error rates of entire sample set were determined based on these parameters.
**. Test (cross-validation) pertains to the full sample set that was divided by 2 and one half was used to determine the classification parameters and the other half was tested
using these parameters
doi: 10.1371/journal.pone.0075670.t005
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Geographic batteries
Immunoglobulin M and IgG multiplex MIA data for each of
the samples from the initial sample set (used to derive the
classification parameters) were assigned to one of the 3
geographic batteries (US, AAE or CSAM). A map of the
proposed batteries is shown in Figure 1. Only the data from the
antigens within the batteries were used. New classification
parameters (cutoffs or probabilities) were derived for each of
the antigens within the batteries, and the error rates for each
method using the full and test (cross-validation) sets are listed
in Table 7 in rows labeled “Init (full/test).”. Error rates were
calculated using both V/N and P/N values together. For the
both the IgM and IgG analyses of the geographic batteries,
LOGITBOOST gave the lowest error rates for both the full data
set and cross-validations. Error rates for LOGITBOOST ranged
from 0.4% (US)-1.9% (AAE) for the full set and 8.94%
(AAE)-11.67% (CSAM) for the cross-validation in the IgM test;
and from 1% (US)-1.2% (CSAM) for the full set and 7.9%
(AAE)-11.6% (CSAM) for the cross-validation in the IgG test.
A separate group of samples with roughly equal numbers
spread between the geographic batteries were used to validate
the classification parameters derived above (Table 1 columns
“Geo Val”). Results in Table 7 (rows labeled “GeoVal”) show
that the error rates are higher than those of the initial data set
for most of the methods.
Summer 2011 evaluation
The classification parameters derived for the geographic
batteries on the initial sample set were applied to IgM multiplex
MIA results from 327 archived samples tested initially by the
traditional methods over the summer of 2011, and to 228 IgG
multiplex MIA results. The samples were divided into
geographic groups based on their origins (Table 2). This
dataset included samples that were equivocal, had dual
infection, had unknown vaccination status, or were
indeterminate. Analyses were performed on those samples that
were diagnostically-conclusive using the 7 multivariate
classification methods in order to generate error rates for the
sample set (Table 7, rows “2011”). This served to identify any
specific trouble spots. Multiplex MIA results from diagnostically
indeterminate samples were reserved for later analysis (see
the following section). Overall, LOGITBOOST gave the lowest
error rates, but these rates were notably high for some of the
viruses within the batteries, in particular LAC in the US IgM
battery, and the negative groups in the US and CSAM
batteries. The source of these errors is illustrated in Figure 2,
where the V/N values of each sample in the original set, the
geographic validation set, and the summer 2011 set for the IgM
test are plotted for each virus. Using Lac as an example, the
V/N’s of the original and geographic validation samples are
higher overall than for the summer 2011 set. This caused
several false negatives to be generated. False positives to SLE
and EEE were also observed.
Combination of samples to form the final models
To address the errors illustrated in Figure 2, all 3 datasets
were combined, effectively doubling the number of data points.
In addition, the amassed data were reviewed manually to
identify any samples that yielded obviously spurious results, to
avoid creating final classification parameters that would be
unduly biased resulting in unnecessary error. These samples
were removed from the analysis. The models were refitted on
the resulting larger sets. Error rates for the geographic
batteries using LOGITBOOST and MLR were improved
considerably (Table 7 rows “Full set”), and are depicted in
Figure 3. Error rates are also shown to illustrate the negative
Table 6. Comparison of apparent error rates (%) generated by using calculated ROC cutoffs and cutoffs of 2.
 IgM     IgG     
 V/N  P/N   V/N  P/N   
Virus Calc. cutoff Cutoff=2 Calc. cutoff Cutoff=2 N IgM Calc. cutoff Cutoff=2 Calc. cutoff Cutoff=2 N Igg
CHIK 1.5* (1.1**) 2 4.5 (2.4) 4.5 61 0.0 (3.7) 0 1.7 (3.9) 10 47
DEN 5.6 (5.4) 20.7 4.4 (5.0) 7.8 89 4.6 (10.6) 24.9 14.9 (4.9) 23.2 73
EEE 2.6 (1.0) 0.9 6.7 (2.1) 6.7 36 0.3 (2.2) 0.6 1.8 (3.1) 4.7 39
JE 2.7 (2.9) 2.4 3.0 (5.9) 6.5 30 3.7 (2.6) 4.9 6.2 (9.5) 24.1 29
LAC 6.5 (1.9) 6.2 10.3 (3.0) 17 78 4.5 (2.9) 5.8 11.2 (4.2) 34 44
MAY 0.0 (14.5) 27.3 0.0 (6.7) 6.3 7 0.0 (9.1) 37.4 0.0 (4.2) 7.2 5
POW 0.3 (3.7) 5.8 0.9 (11.5) 10.4 22 0.6 (18.6) 6.9 1.9 (13.0) 28.9 16
RR 1.1 (5.0) 41.1 12.2 (1.3) 7.8 8 0.0 (6.3) 42.3 1.0 (3.1) 3.6 6
SLE 1.7 (4.1) 5.8 1.1 (11.2) 12.7 56 3.3 (3.8) 8.8 3.3 (13.0) 38.5 61
VEE 16.5 (1.8) 9.5 3.2 (1.9) 3.2 6 0.0 (4.2) 2.7 1.3 (2.8) 5.3 16
WN 0.9 (9.8) 5.7 2.2 (2.8) 2.8 93 1.8 (7.8) 9.8 3.0 (13.4) 16.3 104
YF 14.5 (2.4) 16 9.9 (2.1) 10.6 101 5.3 (5.9) 14.1 5.3 (11.3) 24.2 59
Total*** 5 3 3+1 tied 1 tied  10+3 tied 0 3 tied 0  
* Lowest error rate per test shown in bold
**. Calculated cutoff value
***. Total lowest error rate for each method of cutoff calculation
doi: 10.1371/journal.pone.0075670.t006
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consequences of over-fitting the data using LOGITBOOST
(“Iterations”), to confirm that the number of fitting iterations
used in the final model was near-optimal. Because
LOGITBOOST can result in a tie, error rates are also shown for
when ties predict the correct (tie right) and incorrect (tie wrong)
infecting virus. Indeterminate samples from 2011 (equivocals
and dual infections) were analyzed using LOGITBOOST and
MLR and results are illustrated for IgM only (Table S1). The
applications of post-processing methods are needed to identify
these types of samples during clinical use of the multiplex
MIAs. Overall, LOGITBOOST (where both V/N and P/N values
were included in the model as separate measures) was more
successful than MLR, and was therefore selected as the
classification method of choice.
Cerebrospinal fluid
Thirty seven CSF samples were tested in the 13-virus IgM
multiplex MIA format and analyzed using LOGITBOOST and
MLR in the geographic batteries in which the infecting virus
appeared, less two that were diagnostically indeterminate. In
addition, 71 (US), 7 (AAE) and 3 (CSAM) CSF’s that were part
of the summer 2011 validation sample set were analyzed using
LOGITBOOST and MLR, with 12 indeterminate samples
omitted. The infecting virus was identified correctly for 91%
(US), 94% (CSAM) and 83% (AAE) of the samples using MLR.
The correct virus identification was made for 90 (tie
wrong)-92% (tie right) (US), 89-97% (CSAM) and 86-95%
(AAE) of samples using LOGITBOOST. Details are shown in
Table 8.
Non-arbovirus serum samples
Serum samples known to be positive for syphilis, Lyme
disease IgM, Lyme disease IgG, rheumatoid factor and anti-
nuclear antibody were tested using the multiplex IgM and IgG
MIAs using the entire 13-virus panel to look for any cross-
reactivity. No samples showed evidence of reactivity with any
of the viral antigens in either of the multiplexes.
Table 7. Error rates (%) for all classification methods and geographic testing batteries.
Method Set Type  IgM US IgG-US IgM CSAM IgG CSAM IgM AAE IgG AAE IgM All IgG All
LDA Init Full  30.1 18.0 40.7 18.8 41.3 24.7 38.2 20.6
 Init Test  28.9 17.6 41.7 19.2 40.1 25.6 38.2 19.2
 GeoVal Eval  11.1 0.0 22.5 16.0 21.6 20.0   
 2011 Eval  14.1 4.8 0.0 0.0 22.2 12.5   
SVM - Linear Init Full  10.5 2.8 14.2 6.0 15.3 9.0 12.4 3.9
 Init Test  13.4 7.5 22.4 10.3 20.2 13.0 20.0 10.2
 GeoVal Eval  2.2 3.1 7.5 4.0 10.8 13.3   
 2011 Eval  10.6 7.5 10.0 5.3 17.3 17.5   
SVM - Radial Init Full  3.5 1.2 2.0 2.1 4.4 2.9 1.7 1.5
 Init Test  12.8 9.8 20.9 16.7 13.8 14.5 27.1 20.8
 GeoVal Eval  24.4 9.4 32.5 12.0 18.9 20.0   
 2011 Eval  12.8 18.0 60.0 15.8 16.0 17.5   
Multinomial Init Full  1.8 0.6 5.9 3.1 6.2 3.7 1.9 1.1
 Init Test  16.5 13.3 21.3 17.7 14.7 18.8 24.9 22.6
 GeoVal Eval  26.7 31.3 22.5 76.0 16.2 53.3   
 2011 Eval  33.9 40.6 30.0 84.2 17.3 45.0   
 Full Full  3.5 2.6 4.4 3.1 5.6 5.9   
 Full Test (95% CI) 8.6 (7.5-9.6) 10.1 (8.9-11.2) 16.2 (14.7-17.7) 17.9 (16.3-19.5) 13.9 (12.5-15.2) 19.0 (17.4-20.7)   
Logit Boost Init Full  0.4 1.0 1.0 1.2 1.9 1.4 0.4 0.0
 Init Test  6.3 7.7 12.3 8.1 9.6 11.2 12.4 12.3
 GeoVal Eval  12.8 12.5 8.6 10.5 17.7 13.3   
 2011 Eval  21.3 14.8 30.4 12.5 12.1 12.9   
 Full Full  1.3 1.0 1.1 0.7 1.9 1.7   
 Full Test (95% CI) 7.2 (6.2-8.1) 5.9 (5.0-6.8) 9.7 (8.4-10.9) 9.7 (8.4-10.9) 7.2 (6.1-8.3) 9.0 (7.7-10.3)   
MaxValue - V/N Init Full  24.5 20.8 25.0 31.2 19.0 28.4 23.3 33.9
 Init Test  23.8 20.8 16.3 32.2 19.8 29.1 21.2 33.7
 GeoVa1 Eval  64.4 75.0 27.5 24.0 46.0 20.0   
 2011 Eval  60.9 73.8 60.0 63.2 54.3 37.5   
MaxValue - P/N Init Full  20.6 20.2 21.6 27.6 17.1 27.1 19.9 28.3
 Init Test  20.8 20.1 19.5 30.0 17.0 27.8 18.7 28.5
 GeoVal Eval  57.8 87.5 47.5 68.0 27.0 46.7   
 2011 Eval  40.9 73.8 60.0 84.2 54.3 52.5   
doi: 10.1371/journal.pone.0075670.t007
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Assay controls
Assay controls were added to the IgM and IgG MIAs for each
geographic battery. A negative serum control served as the
denominator for P/N calculations. The negative serum controls
from the initial sample plates were compared to determine the
variability between plates (intra-class correlation (ICC)) and
whether there would be a need for subsequent test plates to be
standardized against the historical controls. We evaluated the
V/N values for the negative controls on all the viral antigens for
within plate and among plate consistency by computing ICCs
and associated 95% CIs. ICC values ranged from 0.87-0.99
with the confidence limits varying from 0.67 (WN) to 0.97
(LAC).
Genus-specific monoclonal antibodies coupled to
phycoerythrin served as antigen verification controls. Means
and standard deviations (SDs) were calculated for these
controls on the viral antigens of their genus, and acceptable
ranges were established (data not shown). These ranges will
form the basis for quality control of subsequent diagnostic
assays, once the method is introduced into the laboratory on a
routine basis, and will be included in the assay analysis
software that is currently under construction. Means, SD’s and
95% content and 95% upper and lower tolerance limits of the
MFIs were calculated for internal control bead sets that were
placed in each test well. Any sample MFI that fell below the
lower 95% tolerance limit for one or more of the instrument
reporter laser, serum or conjugate controls would be repeated.
Sample MFIs for the nonspecific bead reaction control that
were greater than the 95% confidence limit for that bead region
would also be repeated. MFI values for RF were informational
only (See Table S2 for details). Of the 419 serum and CSF
samples tested for IgM in 2011, numbers of samples out of
range were 2 (serum), 12 (RF), 2 (reporter control) and 2
(nonspecific bead reaction). Of the 228 serum samples tested
for IgG in 2011, numbers of samples out of range were 1
(serum), 7 (reporter control) and 0 (nonspecific bead reaction).
Dengue and yellow fever
The antigens used for DEN were a combination of
recombinant DEN 2/3 serotypes; YF was 17D (vaccine strain)
antigen made in suckling mouse brain. The individual
performances of the known positive dengue and yellow fever
(vaccine) serum samples in the13-virus multiplex MIA tests
were assessed to determine a) whether the dengue antigen
combination is sufficient to detect all serotypes from both
primary and secondary infections, and b) to assess whether
yellow fever vaccine recipients could be misclassified as being
infected with alternate flaviviruses. Results from dengue serum
samples of all 4 serotypes comprising both primary and
secondary infections were analyzed using LOGITBOOST.
Figure 1.  Map depicting the areas covered and viruses tested for in the 3 multiplex MIA geographic batteries.  US covers
the US and Canada; CSAM covers Central and South America and the Caribbean; AAE covers Asia, Europe and Africa. Australia
and parts of the South Pacific are not included in the multiplex batteries.
doi: 10.1371/journal.pone.0075670.g001
Multiplex IgM and IgG Immunoassays for Arboviruses
PLOS ONE | www.plosone.org 10 September 2013 | Volume 8 | Issue 9 | e75670
Correct classification was achieved for 98% and 99% of results
from the IgM and the IgG multiplexes, respectively, indicating
that all 4 serotypes, regardless of whether they are primary or
secondary, are capable of being classified correctly using
LOGITBOOST. The single false classification for each test
resulted from a secondary infection (IgM) and a primary
infection (IgG). In addition, 91% of IgM samples gave
classification probabilities of >90% for DEN. In the IgG test,
89% of samples gave classification probabilities >90% for DEN.
Thus, the likelihood of a DEN infection being misclassified as
another flavivirus was shown to be minimal using this analysis
method. Using ROC (the individual method of analysis) 94%
and 97% DEN-positive sera had values of V/N and P/N
respectively that were greater than the calculated ROC cutoffs
(Table 6) in the IgM assay. In the IgG assay, 95% and 84%
had V/N and P/N values respectively that were greater than the
DEN ROC cutoffs. In the IgM test, 1 primary and 4 secondary
samples had V/N values below the cutoff; 1 primary and 1
secondary were below the P/N cut off. In the IgG test, 4
primary samples gave V/N values below the cutoff; in the IgG
test 9 primary and 0 secondary samples were below the P/N
cutoff. To obtain a measure of cross-reactivity between the
flaviviruses as measured by ROC analysis, V/N values for the
known DEN-positive samples tested on heterologous flavivirus
antigens were analyzed. Values were found to be greater than
the ROC cutoffs for WN (68%), SLE (35%), POW (2%), JE
(60%), and YF (60%). When the absolute V/N values were
compared, DEN V/N’s were 7 to 18 times higher to the dengue
antigen than to the other viruses. The same trend was true for
the IgG test, where 100% of DEN V/N’s were 2.5 to 5 times
Figure 2.  True classification vs. test value – IgM based on V/N.  True classification (y-axis) refers to the original diagnostic
result based on the traditional screening method plus plaque reduction neutralization, and test value (x-axis) is the V/N
measurement for each sample. Samples in each set used in the analyses are depicted: black dots represent the initial set; red dots
represent the geographic validation set; blue dots represent the summer 2011 set. Sample rows for the infecting virus are shaded
grey in each antigen panel.
doi: 10.1371/journal.pone.0075670.g002
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greater to the dengue antigen than to the other viruses. To test
whether YF vaccine might be erroneously classified as a
different flaviviral infection using the IgM test, the same type of
V/N comparison was performed for the samples from YF
vaccine recipients. Positive ROC results were obtained to WN
(7%), SLE (7%), POW (1%), DEN (14%) and JE (7%), where
the YF V/N’s were 5.5 to 19-times greater to the YF antigen
than to the other viruses.
Cross-reactivity of flaviviruses in the multiplex MIA
versus ELISA
To partially evaluate whether the multiplex MIA
demonstrated flavivirus cross-reactivity greater or less than the
standard screening ELISA, an Arbovirus Diseases Branch
database search was performed for IgM and IgG ELISA results
of sera from confirmed SLE cases, because SLE represents
one of the most serologically cross-reactive viruses in the
genus. Results were compared from SLE antibody-positive
samples where antibodies to DEN and WN viruses were also
tested for, and where any samples with P/Ns of >2 were
considered positive. The cross-reactivity’s seen for IgM ELISA
using SLE-IgM positive samples were: DEN 42% (N=54); WN
85% (N=108). The cross-reactivity’s seen for IgG ELISA using
SLE-IgG positive samples were: DEN 31% (N=26); WN 85%
(N=64). By comparison, the multiplex MIA results using ROC
cutoff’s shown in Table 6 gave cross-reactivity’s using SLE-IgM
positive samples of: DEN 78% (N=54); WN 68% (N=54). The
cross-reactivity’s seen for multiplex MIA IgG using ROC cutoff’s
with SLE-IgG positive samples were: DEN 86% (N=59); WN
78% (N=59). LogitBoost results for the IgM multiplex MIA
where the probabilities were >20% of the 59 SLE-positive
samples being classified as DEN and WN were 13% and 0%
Figure 3.  Error rates (%) for full data classification.  Error rates (y-axes) where 1.0 is 100% incorrect classification (i.e. includes
false positives and false negatives) are shown for the combined data set comprising the initial, geographic and summer 2011
sample sets. Error rates are shown for the 2 best classification options, multinomial linear regression (Multi) and logitboost (logit) on
the x-axes. Full and test error rates are described in the analysis section of Materials and Methods. Logit. tie right/tie wrong is where
the results that are tied are included in the error rates as being right or wrong. Logit. iteration is where more iterations of the
classification scheme are performed than normally would be (usually equal to the number of data points in the set). This results in
increased error rates due to over-fitting of the data such that any sample variation outside of the limits of the sample set used for
deriving the classification rules results in an error.
doi: 10.1371/journal.pone.0075670.g003
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respectively and where the probabilities were >10% of being
classified as DEN and WN were 20% and 0% respectively. For
the IgG multiplex MIA, the probabilities at the 20% Logitboost
level were 2% and 2% for DEN and WN respectively; at the
10% level, probabilities were 17% and 5% respectively.
Discussion
The multiplexing capability of the BioPlex (Luminex) platform
allows for a single small sample to be simultaneously tested
against multiple viral antigens, which is advantageous over
methods such as ELISA because results are generated at the
same time under the same conditions. The ability of these
assays to incorporate internal controls further validates the
results. From a practical standpoint, the ability to prepare
reagents for several months of testing at one time streamlines
the routine use of the multiplex MIAs. To facilitate the practical
setup of these multiplex tests, an Excel® workbook was
devised to calculate the amounts of reagents needed per test
based on sample origin, to guide sample/plate orientation, to
track lot numbers of reagents and to provide specific operating
procedures. The multiplexes also reduce buffer usage and
plastics consumption.
The challenge when dealing with the large amount of data
produced by these assays is to devise a method that
successfully harnesses the power of the multiplexing
arrangement, produces an accurate result output, and is
programmable for everyday use. Quadratic discriminant
analysis, used previously [7], was unsuitable in the context of
these expanded multiplexes. Therefore we compared 8
different analysis methods in IgM and IgG multiplexes, and
evaluated the best of these by using additional samples
assigned to geographic batteries based on the sample origin.
The method that emerged as most useful was LogitBoost. For
practical purposes, the probabilities generated by this method
can be used not only to indicate the infecting virus, but also to
rank close contenders that might have probabilities greater
than for being negative. This informs the decision of which
cross-neutralization tests should be performed, if applicable.
LogitBoost has the advantage of potentially producing tied
results, useful for identification of dual infections or equivocals.
The resulting algorithm is relatively easy to program in Visual
Basic® in Excel® (Microsoft Corp., Redmond, WA). The
comprehensive output generated for the multiplexing method
by LogitBoost captures and presents the data in a way that
individual antigen analysis methods cannot accomplish, and
the comparative error rates for the analysis methods
underscore this utility.
The serodiagnostic portion of the clinical case definition
adopted by the CDC for these viruses takes the following
general format: Fourfold or greater change in virus-specific
serum antibody titer (in quantitative tests between acute and
convalescent specimens), or virus-specific IgM in cerebrospinal
fluid (CSF), or virus-specific IgM demonstrated in serum and
confirmed by demonstration of virus-specific IgG in the same or
a later specimen by a different type of serological assay. A
case will be classified as probable if confirmatory test results
are not obtained [22]. Results from IgG testing using ELISA or
MIA do not factor into the clinical case definitions for these
viruses. However, the data from IgG tests are useful in a)
corroborating results of the IgM tests, b) providing evidence of
a previous arboviral infection when IgM is not detectable, c)
indicating an anamnestic response, especially in secondary
DEN viral infections, and d) pointing the diagnosis toward an
unsuspected arboviral infection due to the presence of intra-
genus cross-reactive IgG antibodies.
Table 8. Multinomial and Logitboost outcomes for CSF.
US battery       CSAM battery      AAE battery      
Multinomial       Multinomial      Multinomial      
 Truth       Truth      Truth     
Predicted LAC NEG POW WN Pred Total Predicted NEG WN yf vacc Pred Total Predicted JE NEG WN yf vacc Pred Total
LACIgM 8    8  NEGIgm 21 1  22  JEIgM 2  3  5
NEGIgM 2 74  1 77  WNIgM  11  11  NEGIgm  24 1  25
POWIgM  1 3  4  YFIgM 1  1 2  POWIgM 1 1   2
SLEIgM    2 2  Truth total 22 12 1 35  WNIgM   8  8
WNIgM 1 1  21 23        YFIgM  1  1 2
Truth total 11 76 3 24 114        Total 3 26 12 1 42
US battery       CSAM battery      AAE battery      
LogitBoost       LogitBoost      Logitboost      
 Truth       Truth      Truth     
Predicted LAC NEG POW WN Pred Total Predicted NEG WN yf vacc Pred Total Predicted JE NEG WN yf vacc Pred Total
LACIgM 6  1  7  NEGIgM 20 1  21  JEIgM 3  1  4
NEGIgM 2 74  1 77  WNIgM  10  10  NEGIgM  23 1  24
POWIgM  1 1  2  YFIgM   1 1  WNIgM   9  9
WNIgM 1 1  23 25  Tie 2 1  3  YFIgM    1 1
Tie 2  1  3  Truth total 22 12 1 35  Tie  3 1  4
Truth total 11 76 3 24 114        Total 3 26 12 1 42
doi: 10.1371/journal.pone.0075670.t008
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For the past 15 years, the Arboviral Diseases Branch at CDC
has used ELISA to test for IgM and IgG to arboviruses [5,6].
Testing involves the reaction of an aliquot of diluted serum on a
separate plate for each arbovirus indicated by the domestic or
travel history of the patient, which may amount to 6 or more
plates. This can be an inefficient use of time, reagents, sample
and supplies. Recently, MIAs have been developed to detect
IgM antibodies to WN and SLE viruses in a duplex
arrangement [7], and also to detect IgM to EEE virus
(unpublished). To perform the IgM and IgG multiplex MIAs in
their entirety for each sample on a routine basis would be
excessive and wasteful of reagents. The method used for
triaging samples in the Arbovirus Diseases Branch diagnostic
lab at the CDC is to test them according to a battery of
arboviruses known to circulate in particular geographic
locations. Currently, there are 9 geographic batteries (western
US, eastern US, Europe, Asia, Central America, Africa, South
America, South Pacific and Australia). To strike a balance
between efficiency in use of reagents and complexity of test
setup, the number of batteries for the MIAs was reduced to 3
(US, Asia/Africa/Europe (AAE), and Central/South America
(CSAM), which took advantage of the large degree of
duplication of viruses within these expanded batteries.
Australia was not included as the only antigen in the multiplex
specific to Australia is RR, and this can be performed ad hoc.
An antigen preparation suitable for detecting anti-Murray Valley
encephalitis virus antibodies using MIA was not available, so
this and some other rarely needed tests will remain as ELISAs
for the time being in our laboratory. The new geographic
battery virus allocation appeared to work well and will simplify
workflow.
The increased error rates seen when the geographic
validation sets were tested is largely due to the relatively small
numbers of samples for each virus within the groups; therefore
one wrong result can make a large difference in error rate. As
with any statistically-based model, the more data points there
are in a set, the more accurate the predictions. To achieve this,
all 3 data sets were combined to produce a final working model
for use in the laboratory. This improved the error rates
considerably for some groups. It should be noted that some
viruses such as MAY were poorly represented and the strength
of the models for these were not as great. In situations where
only a few known positives with high V/N and P/N’s were
available to establish the classification rules, there is the
possibility that true positives with much lower values could
occur. These may be classified incorrectly as negative, as the
cutoff, regardless of classification method, would be impossible
to determine accurately. To address this issue and those of
background reactions and equivocal results, post-processing of
results will be implemented within the context of an Excel®
add-in which is currently in development. This will integrate
with the Excel output of the BioPlex instrument to generate
probabilities by using LOGITBOOST. Results for a specimen
reacted on each viral antigen in the test batteries will be
ranked, where the antigen with the greatest classification
probability is reported as the infecting virus. The ROC data
reported here gives individual V/N and P/N cutoffs for each
viral antigen, and these can be used as a secondary measure
to cross-check the results. For viruses where ROC cutoffs were
derived from very small numbers of samples (e.g., MAY, POW,
WEE) V/N and P/N cutoffs of 2.0 may be used, as confidence
was low in the empirically-derived cutoffs and 2.0 is a number
that has traditionally been used with ELISA, despite the low
error rates seen with the calculated cutoffs. Additional post-
processing will be used to identify the following categories: a)
background reactions due to nonspecific activity of the samples
to antigens causing false positive results, where V/N < ROC
cutoff and P/N > ROC cutoff; b) indeterminate results where
V/N > ROC cutoff but P/N < ROC cutoff; c) V/N and P/N are
both > ROC cutoff, but LOGITBOOST probabilities are too
close to call such that the infecting virus cannot be identified; d)
equivocal results where the highest probability is close to that
of the negative group. It should be noted that the outputs of the
multiplexed arboviral MIAs are not quantitative in terms of
comparing the amount of specific antibody in a sample.
The reasonably common situation arises where a sample
needs testing for a virus that does not appear in the geographic
battery related to its origin or is newly recognized as being
important, for example Jamestown Canyon in the US and
Canada [23] or recently, where DEN has been shown to be
transmitted in the Florida Keys [24]. In this type of situation,
viral antigens can easily be tested for on an ad hoc basis in
addition to any geographic battery, and ROC can be used to
determine reactivity to these antigens outside of the Excel add-
in. Arboviral serosurveys that usually involve the testing of
samples with only one or two antigens can utilize ROC cutoffs
alone. However, LogitBoosting can conceivably be used under
these circumstances with some further programming for use
with flexible batteries, an ideal we are pursuing.
The ICC data suggested a small degree of plate to plate
variation but the decision to normalize plates to mitigate this
effect will be made when the Excel® Add-in had been
completed, so that results can be compared for some positive
samples using the finalized algorithm. It was observed that
when the magnitude of the MFIs of the negative controls on a
plate varied, the test samples varied similarly; hence the need
for plate to plate comparison may be mitigated.
This study contains data regarding previously-understood but
unpublished information regarding the degree of cross-
reactivity between arboviruses, which is useful for purposes of
test development and interpretation of results. This was
discussed briefly in relation to DEN and YF. In addition, a
glimpse into the cross-reactivity of ELISA versus multiplex MIA
was illustrated by looking at the results when SLE-positive
samples were tested in WN and DEN assays. The ROC cutoff
method for MIA showed that cross-reactivity is detected in the
multiplex as much if not more than in the ELISA (possibly due
to a marginally greater sensitivity of the MIA), but that
LogitBoost can be expected to yield greater viral specificity
when applied to the MIA. In addition, these data may provide
insight regarding the capability of combined IgM and IgG
testing results to reduce the need for confirmatory PRNT’s in
some instances. An in-depth analysis of both of these facets,
while of great interest, is outside the scope of the current
paper.
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The Luminex platform has been used extensively for
multiplexed testing for viruses in the diagnostic arena. The vast
majority of these tests are for identification of virus-specific
nucleic acid material [25,26]. Recently, multiplexing methods
for serodiagnosis have been developed [27,28]. Many of these,
such as Lammie et al. 2012 [29], take advantage of the method
to test for etiologic agents of a disparate nature where
antibodies are easily identified from one another. The choice of
classification method may not be particularly critical under
these circumstances. Here, we focus on very closely-related
arboviruses, the antibodies to which frequently cross-react
among the genuses, thus rendering analysis more challenging.
This work represents both the most comprehensive, validated
multiplexing method for arboviruses to date, and also the most
systematic attempt at determining the most useful classification
method for use with these serologic tests.
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